Good Steward Wealth Advisors LLC Has $398,000 Stake in Eli Lilly and Company $LLY

Good Steward Wealth Advisors LLC decreased its position in Eli Lilly and Company (NYSE:LLY) by 11.9% during the 2nd quarter, Holdings Channel.com reports. The firm owned 511 shares of the company’s stock after selling 69 shares during the period. Good Steward Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $398,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in LLY. Duquesne Family Office LLC boosted its stake in shares of Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after buying an additional 32,640 shares during the period. Corient IA LLC bought a new stake in shares of Eli Lilly and Company in the first quarter valued at approximately $570,000. LS Investment Advisors LLC boosted its stake in shares of Eli Lilly and Company by 1.7% in the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company’s stock valued at $1,933,000 after buying an additional 40 shares during the period. Cutter Capital Management LP bought a new stake in shares of Eli Lilly and Company in the first quarter valued at approximately $14,866,000. Finally, Prism Advisors Inc. bought a new stake in shares of Eli Lilly and Company in the first quarter valued at approximately $207,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Leerink Partnrs cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. HSBC upgraded shares of Eli Lilly and Company from a “reduce” rating to a “hold” rating and boosted their price objective for the company from $675.00 to $700.00 in a research report on Wednesday, August 27th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Cantor Fitzgerald lowered their price objective on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating for the company in a research report on Wednesday, August 13th. Finally, Leerink Partners restated a “market perform” rating and set a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $941.35.

Insiders Place Their Bets

In related news, CEO David A. Ricks acquired 1,632 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director J Erik Fyrwald acquired 1,565 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares of the company’s stock, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 4,514 shares of company stock valued at $2,894,841 over the last ninety days. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Trading Down 0.2%

Shares of LLY stock opened at $754.90 on Friday. The firm has a market capitalization of $714.48 billion, a P/E ratio of 49.34, a P/E/G ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $942.35. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The stock’s fifty day simple moving average is $741.03 and its 200 day simple moving average is $776.40.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Friday, August 15th. Eli Lilly and Company’s dividend payout ratio is presently 39.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.